Yada manyan B-cell lymphoma (DLBCL) -04

Mista Li, mai shekaru 64 (pseudonym), an gano shi yana da manyan ƙwayoyin lymphoma B-cell (DLBCL) shekaru huɗu da suka wuce, wanda ya ci gaba zuwa ƙarshen sa hannu na splin, hakarkarinsa, huhu, da pleura, wanda aka rarraba a matsayin mataki na IV. . Bayan maganin rigakafi na farko, yanayinsa ya kasance cikin gafara sama da shekaru uku. Koyaya, a cikin Maris na shekarar da ta gabata, cutarsa ​​ta sake dawowa, wanda ya haɗa da nodes na retroperitoneal da yawa. Duk da chemotherapy na layi na biyu, kawai ya sami gafarar ɗan adam kuma ya lalace cikin sauri, yana buƙatar ƙarin ingantaccen magani don sarrafa ci gaba.

Da yake fuskantar wannan ƙalubale mai ban tsoro, ƙungiyar kwararru a asibitin Lu Daopei sun yi nazari sosai kan lamarin Mr. Li tare da kira taron ƙungiyar da'a daban-daban (MDT) don ba da shawarar maganin ƙwayoyin cuta na CAR-T. CAR-T cell far, a matsayin sabon nau'i na ƙwayar cuta immunotherapy, yana ba da fa'idodi masu mahimmanci kamar ƙaƙƙarfan niyya da tasiri mai dorewa ga marasa lafiya tare da sake dawowa da lymphoma.

A cikin Janairu 2023, Mista Li ya yi amfani da maganin tantanin halitta CAR-T a Sashen Lymphoma. Kafin jiyya, an yi amfani da biopsy na nodes na inguinal na dama, wanda ya tabbatar da ingancin CD19 da CD20, yana ba da maƙasudin maƙasudin maganin CAR-T. A karkashin jagorancin Farfesa Li, ƙungiyar likitocin sun tsara tsarin kulawa na musamman.

A ranar 25 ga Yuli, 2023, Mista Li ya kammala aikin jiko na sel CD19/20 CAR-T, wanda ya gudana cikin kwanciyar hankali karkashin kulawar kwararrun likitocin. Duk da fuskantar ciwon saki na cytokine, cytopenia, da kamuwa da cuta yana haifar da haɗari bayan jiko, kulawar tallafi mai ƙarfi ya sami nasarar sarrafa mummunan halayen yayin jiyya.

Watanni shida bayan aiwatar da maganin tantanin halitta na CAR-T, Mista Li bai nuna wani lahani mai mahimmanci a cikin jikinsa ba, yana samun cikakkiyar amsawar rayuwa (CMR), wanda ya kawo sabon fata ga lafiyarsa. Ƙungiyar likitocin ta kara daɗaɗa ragowar raunuka na retroperitoneal tare da aikin rediyo don tabbatar da cikakkiyar farfadowar cututtuka da kwanciyar hankali na dogon lokaci.

Ta hanyar wannan maganin rigakafi na CAR-T cell, Mista Li ba kawai ya sami ci gaba sosai a yanayinsa ba amma ya sake samun kwarin gwiwa da kuzari a rayuwa. Shari'ar sa tana ba da sabon bege da jagora ga marasa lafiya na lymphoma kuma yana nuna yuwuwar da inganci na CAR-T tantanin halitta a cikin kula da lymphoma refractory.

CAR-T cell far, a matsayin sabon maganin ciwon daji, yana canza yanayin rayuwar marasa lafiya tare da lymphoma mai raɗaɗi. A karkashin kulawar kwararrun kwararru a Sashen Lymphoma, karin majinyata kamar Mista Li na iya sa ran samun gagarumin ci gaba a rayuwa da ingancin rayuwa. Duba gaba, ƙarin ci gaba da aikace-aikace na CAR-T cell far sun yi alƙawarin buƙatu masu fa'ida da yuwuwar maganin cutar kansa.